Nature Reviews Neurology - Table of Contents alert Volume 10 Issue 4

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
April 2014 Volume 10 Number 4
Impact Factor 15.518 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Huntington disease: natural history, biomarkers and prospects for therapeutics Christopher A. Ross, Elizabeth H. Aylward, Edward J. Wild, Douglas R. Langbehn, Jeffrey D. Long, John H. Warner, Rachael I. Scahill, Blair R. Leavitt, Julie C. Stout, Jane S. Paulsen, Ralf Reilmann, Paul G. Unschuld, Alice Wexler, Russell L. Margolis & Sarah J. Tabrizi
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Nature Reviews Neuroscience  FREE POSTER - BDNF function in health and disease  This Poster summarizes the molecular functions of BDNF in the CNS and highlights its therapeutic potential for conditions such as Alzheimer's disease, Parkinson's disease, stroke and spinal cord injury. This poster is freely available thanks to support from  EVER Neuro Pharma
RESEARCH HIGHLIGHTS Top Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma Published online: 18 March 2014 p179 | doi:10.1038/nrneurol.2014.47 PDF Prion disease: Cerebrospinal fluid tau levels—a potential diagnostic biomarker for Creutzfeldt-Jakob disease Published online: 11 March 2014 p180 | doi:10.1038/nrneurol.2014.39 PDF Parkinson disease: A role for serotonergic neurons in levodopa-induced dyskinesia Published online: 18 March 2014 p180 | doi:10.1038/nrneurol.2014.41 PDF Motor neuron disease: High-calorie diet might delay amyotrophic lateral sclerosis Published online: 11 March 2014 p181 | doi:10.1038/nrneurol.2014.40 PDF Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis Published online: 18 March 2014 p182 | doi:10.1038/nrneurol.2014.48 PDF IN BRIEF Epilepsy: Mapping epileptic foci with foramen ovale electrodes | Alzheimer disease: Comparable brain levels of amyloid-β and tau in asymptomatic AD and mild cognitive impairment | Migraine: Noninvasive vagus nerve stimulation to relieve migraine | Neurosurgery: Ultrasound imaging of the brain during surgery | Neuro-oncology: Pregnancy might promote progression of high-grade gliomas | Huntington disease: Possible cellular mechanism for striatal degeneration in Huntington disease | Neurodegenerative disease: Potential adverse effects of histone deactylase inhibition in spinocerebellar ataxia type 1 PDF Neurology JOBS of the week Research Assistant - fMRI connectivity of the Mouse Brain Istituto Italiano di Tecnologia (IIT) Postdoctoral Fellow Position Examining The Impact Of The Neonatal Immune System On Perinatal Brain Injury University of Gothenburg (GU) UKRMP Postdoctoral Research Fellow University of Edinburgh Microvascular Dysfunction In Neurodegenerative Diseases - Postdoc Position Available- Lund University More Science jobs from Neurology EVENT Molecular Neurology and Therapeutics 12.07.14 Cambridge, UK More science events from
NEWS AND VIEWS		Top
Multiple sclerosis: TOWER confirms the efficacy of oral teriflunomide in MS Aiden Haghikia & Ralf Gold Published online: 18 March 2014 p183 | doi:10.1038/nrneurol.2014.42 Results of the TOWER phase III trial confirm the efficacy of teriflunomide in relapsing-remitting multiple sclerosis (RRMS). With seven substances now approved for RRMS, individualized treatment for the inflammatory aspect of the disease is within reach, although many questions remain unanswered, particularly concerning the neurodegenerative aspect RRMS. Full Text | PDF
Dementia: The complexities of comorbidity in dementia Christopher M. Callahan & Cathy C. Schubert Published online: 18 March 2014 p184 | doi:10.1038/nrneurol.2014.46 A large claims-based study has identified several comorbidity clusters in individuals with dementia, corroborating the notion that comorbid conditions are an important contributor to health outcomes. The complexity of comorbidities calls for a patient-centred approach for care. Importantly, good management of comorbidities can improve quality of life in progressive dementia. Full Text | PDF
Parkinson disease: Gene therapy for Parkinson disease—a hope, or a dream? C. Warren Olanow Published online: 25 March 2014 p186 | doi:10.1038/nrneurol.2014.45 Gene therapy offers the potential to deliver therapeutic proteins to a target region, and is a promising treatment for Parkinson disease. A new open-label study testing ProSavin®, which encodes three rate-limiting enzymes required for dopamine biosynthesis, showed favourable safety and efficacy results, but its therapeutic potential awaits confirmation in double-blind trials. Full Text | PDF
Alzheimer disease: Lessons from immunotherapy for Alzheimer disease Yan-Jiang Wang Published online: 18 March 2014 p188 | doi:10.1038/nrneurol.2014.44 Amyloid-β (Aβ) is suggested to have a pivotal role in the pathogenesis of Alzheimer disease (AD) and is a major therapeutic target. Recent phase III trials of the anti-Aβ monoclonal antibodies bapineuzumab and solanezumab, which failed to improve cognitive function in patients, provide valuable insights for the future development of immunotherapies. Full Text | PDF
REVIEWS		Top
Neuroprognostication of hypoxic-ischaemic coma in the therapeutic hypothermia era David M. Greer, Eric S. Rosenthal & Ona Wu Published online: 11 March 2014 p190 | doi:10.1038/nrneurol.2014.36 Neurological prognostication in patients who remain in hypoxic-ischaemic coma after cardiac arrest has always been challenging, and has become even more so since the advent of therapeutic hypothermia (TH). In this Review, Greer et al. consider how neurological outcomes and prognostic indicators might be influenced by the use of TH, and discuss advances in neuroimaging and electrophysiology that are expected to aid neuroprognostication in this patient population. Abstract | Full Text | PDF
Huntington disease: natural history, biomarkers and prospects for therapeutics Christopher A. Ross, Elizabeth H. Aylward, Edward J. Wild, Douglas R. Langbehn, Jeffrey D. Long, John H. Warner, Rachael I. Scahill, Blair R. Leavitt, Julie C. Stout, Jane S. Paulsen, Ralf Reilmann, Paul G. Unschuld, Alice Wexler, Russell L. Margolis & Sarah J. Tabrizi Published online: 11 March 2014 p204 | doi:10.1038/nrneurol.2014.24 Huntington disease (HD) is considered to be a model neurodegenerative disorder, in that it is caused by a single genetic mutation and is amenable to predictive genetic testing, enabling the entire disease course to be studied. Ross et al. describe the natural history of HD, including the timing of emergence of motor, cognitive and emotional impairments. Building on this information, they review recent progress in the development of biomarkers for HD, and potential future roles of these biomarkers in clinical trials. Abstract | Full Text | PDF
Microglial priming in neurodegenerative disease V. Hugh Perry & Clive Holmes Published online: 18 March 2014 p217 | doi:10.1038/nrneurol.2014.38 As a response to accumulation of debris and abnormally folded proteins during neurodegeneration, microglia multiply and adopt a chronically activated state. This process, referred to as priming, makes microglia susceptible to a secondary inflammatory stimulus, often arising from a systemic disorder with an inflammatory component, such as diabetes. Primed microglia react to the secondary inflammatory stimulus with an exaggarated response, which can further exacerbate neurodegeneration. Abstract | Full Text | PDF
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis Manuel A. Friese, Benjamin Schattling & Lars Fugger Published online: 18 March 2014 p225 | doi:10.1038/nrneurol.2014.37 Great progress has been made in elucidating the acute inflammatory components of multiple sclerosis (MS), but the pathophysiological mechanisms of the concomitant neurodegeneration are poorly understood. Friese and colleagues review the current state of knowledge regarding the pathological mechanisms of neuroaxonal dysfunction and injury in MS, highlighting evidence that axonal and neuronal impairment are early and independent contributors to disease progression. Abstract | Full Text | PDF | Supplementary information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2012. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.